Zealand Pharma: Clinical Trials

16 trials sponsored by Zealand Pharma, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

12 completed, 3 recruiting, 1 terminated. 16 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	16	Completed 12, Recruiting 3, Terminated 1

Follow Zealand Pharma: new trials by email

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period ZP9830, Placebo - Plaque Psoriasis	Phase 1	Recruiting	Zealand Pharma	32	2026-07-22	2026-07-29
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function Petrelintide - Impaired Hepatic Function	Phase 1	Recruiting	Zealand Pharma	36	2026-05-18	2026-07-06
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations Petrelintide - Obesity & Overweight	Phase 1	Completed	Zealand Pharma	48	2025-12-17	2026-04-08
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function Petrelintide - Renal Impairment	Phase 1	Completed	Zealand Pharma	39	2025-04-15	2026-01-28
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Dapiglutide 7.5 mg - Overweight and Obesity	Phase 1	Completed	Zealand Pharma	30	2024-12-23	2025-05-06
A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants ZP9830, Placebo - Healthy Volunteers	Phase 1	Recruiting	Zealand Pharma	124	2024-11-12	2026-02-17
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 ZP7570, Placebo - Safety and Tolerability	Phase 1	Terminated	Zealand Pharma	84	2023-09-15	2025-04-25
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants ZP8396, Drug: Placebo (ZP8396) - Overweight, Healthy Volunteers	Phase 1	Completed	Zealand Pharma	68	2022-11-07	2024-06-18
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants ZP8396, Placebo (ZP8396) - Overweight, Healthy Volunteers	Phase 1	Completed	Zealand Pharma	64	2021-10-19	2023-01-17
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector. Glepaglutide - Healthy	Phase 1	Completed	Zealand Pharma	85	2020-03-04	2021-07-14
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function Glepaglutide - Renal Impairment	Phase 1	Completed	Zealand Pharma	16	2019-12-10	2020-11-18
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration Dasiglucagon, Placebo - Hypoglycemia	Phase 1	Completed	Zealand Pharma	60	2018-11-07	2021-03-23
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Glepaglutide - Healthy Subjects	Phase 1	Completed	Zealand Pharma	75	2017-09-04	2017-12-22
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 ZP4207, Placebo - Hypoglycemia	Phase 1	Completed	Zealand Pharma	24	2015-04-01	2015-11-11
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator ZP4207, Glucagon - Hypoglycemia	Phase 1	Completed	Zealand Pharma	111	2014-12-01	2016-01-22
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose ZP1848 - Inflammatory Bowel Disease	Phase 1	Completed	Zealand Pharma	66	2009-01-01	2010-11-02

Conditions studied

Interventions

Countries

Top investigators

Results publications

NIH funding